Ligand-targeted therapeutics in anticancer therapy

@article{Allen2002LigandtargetedTI,
  title={Ligand-targeted therapeutics in anticancer therapy},
  author={T. Allen},
  journal={Nature Reviews Cancer},
  year={2002},
  volume={2},
  pages={750-763}
}
  • T. Allen
  • Published 2002
  • Medicine
  • Nature Reviews Cancer
Cytotoxic chemotherapy or radiotherapy of cancer is limited by serious, sometimes life-threatening, side effects that arise from toxicities to sensitive normal cells because the therapies are not selective for malignant cells. So how can selectivity be improved? One strategy is to couple the therapeutics to antibodies or other ligands that recognize tumour-associated antigens. This increases the exposure of the malignant cells, and reduces the exposure of normal cells, to the ligand-targeted… Expand
Principles in the design of ligand-targeted cancer therapeutics and imaging agents
TLDR
This Review describes the major principles in the design of ligand-targeted drugs and provides an overview of lig and–drug conjugates and ligand–imaging-agent conjugate that are currently in development. Expand
Biologics in Targeted Cancer Therapy
TLDR
This chapter presents an overview with preclinical and clinical data for different agents which were turned into targeted therapeutics and their conjugation/fusion to tumor-specific antibodies. Expand
Nanoparticle targeting of anti-cancer drugs that alter intracellular signaling or influence the tumor microenvironment.
Nanoparticle-based therapeutics are poised to become a leading delivery strategy for cancer treatment because they potentially offer higher selectivity, reduced toxicity, longer clearance times, andExpand
Arming antibodies for cancer therapy.
  • P. Polakis
  • Medicine
  • Current opinion in pharmacology
  • 2005
TLDR
Myriad formulations involving radionuclides, bacterial toxins and small-molecule drugs linked to antibodies through peptides, protein fusions and chelating agents are in preclinical and clinical evaluation, and a few have been approved as human medicines. Expand
Monoclonal antibodies in therapy of solid tumors.
Monoclonal antibodies have become increasingly used therapeutic agents for the treatment of solid cancer. Many are now being tested as components of adjuvant or first-line therapies to assess theirExpand
Gemcitabine Peptide-Based Conjugates and Their Application in Targeted Tumor Therapy
TLDR
This work summarizes recently published gemcitabine peptide-based conjugates and their efficacy in anticancer therapy and focuses on the direct targeting of chemotherapeutics to cancer cells using the drug-peptide conjugacy. Expand
Antibody targeted drugs as cancer therapeutics
TLDR
Recent preclinical and clinical data for antibody–drug conjugates and fusion proteins with a special focus on drug components that exert their antitumour effects through normal biological processes are discussed. Expand
Ligand-Mediated Targeting: An Update
TLDR
Many nanoparticle delivery systems for anticancer drugs have also entered the clinic and have been shown to have improved anticancer effects over conventional chemotherapeutic drugs due to their ability to improve the pharmacokinetics and pharmacodynamics of their associated drugs. Expand
Ligand-Mediated Targeting: An Update
  • T. Allen
  • Computer Science
  • 2004 International Conference on MEMS, NANO and Smart Systems (ICMENS'04)
  • 2004
TLDR
Many nanoparticle delivery systems for anticancer drugs have also entered the clinic and have been shown to have improved anticancer effects over conventional chemotherapeutic drugs due to their ability to improve the pharmacokinetics and pharmacodynamics of their associated drugs. Expand
Synthesis and biological evaluation of novel taxoids designed for targeted delivery to tumors.
TLDR
These taxoids now meet the high potency required for use in a targeted-delivery approach using monoclonal antibodies, and are prepared with significantly higher cytotoxicity than paclitaxel and docetaxel. Expand
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 147 REFERENCES
Receptor-mediated and enzyme-dependent targeting of cytotoxic anticancer drugs.
TLDR
This review is a survey of various approaches to targeting cytotoxic anticancer drugs to tumors primarily through biomolecules expressed by cancer cells or associated vasculature and stroma and focuses on a mechanistic understanding of selective drug release or generation at the tumor site. Expand
Selective activation of anticancer prodrugs by monoclonal antibody-enzyme conjugates.
TLDR
This review focuses on the activities of several mAb-enzyme/prodrug combinations, with an emphasis on those that have provided mechanistic insight, clinical activity, novel protein constructs, and the potential for reduced immunogenicity. Expand
Optimizing liposomes for delivery of chemotherapeutic agents to solid tumors.
There are many potential barriers to the effective delivery of a drug in its active form to solid tumors. Most small-molecule chemotherapeutic agents have a large volume of distribution on i.v.Expand
Selective activation of anticancer prodrugs by monoclonal antibody-enzyme conjugates.
  • P. Wallace, P. Senter
  • Chemistry, Medicine
  • Methods and findings in experimental and clinical pharmacology
  • 1994
TLDR
The method of using targeted enzymes for prodrug activation can be extended to include prodrugs that release very potent drugs, such as palytoxin, a marine natural product, and to treat cells that have the multidrug resistance phenotype. Expand
Improving the efficacy of antibody-based cancer therapies
TLDR
A quarter of a century after their advent, monoclonal antibodies have become the most rapidly expanding class of pharmaceuticals for treating a wide variety of human diseases, including cancer, and many innovative approaches stand poised to improve the efficacy of antibody-based therapies. Expand
Effective targeted cytotoxicity of neuroblastoma cells.
TLDR
This study demonstrates creation of a novel fusion toxin with effective GD(2)-targeted cellular toxicity and further investigation of this fusion toxin as a therapeutic agent in the management of neuroblastoma is warranted. Expand
Liposome targeting to tumors using vitamin and growth factor receptors.
TLDR
This chapter summarizes various strategies and advances in targeting liposomes to vitamin and growth factor receptors in vitro and in vivo with special emphasis on two extensively studied liposome-targeting systems utilizing folate receptor and HER2/neu growth factor receptor. Expand
Folate-targeted liposomes for drug delivery
TLDR
Folate, as a targeting ligand, offers unique advantages over immunoliposomes, i.e., easy liposomal incorporation, low cost, high receptor affinity and tumor specificity, extended stability, and potential lack of immunogenicity. Expand
Therapeutic opportunities for targeted liposomal drug delivery
Abstract One way to increase the therapeutic index of drugs such as anticancer drugs, which have low therapeutic indices would be by specifically targeting the drugs to the diseased cells. This canExpand
In vitro and in vivo targeting of immunoliposomal doxorubicin to human B-cell lymphoma.
TLDR
It is inferred that targeted anti-CD19 liposomes containing the anticancer drug DXR may be selectively cytotoxic for B cells and may be useful in the selective elimination of circulating malignant B cells in vivo. Expand
...
1
2
3
4
5
...